Sanofi Pasteur ships influenza virus vaccine to US
The shipment represents more than 60 million doses of seasonal influenza vaccine the company plans to deliver to health care providers in the US this influenza season. Sanofi
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).